Suicide and schizophrenia: a systematic review of rates and risk factorsSocial communication and its disorder in autism and Asperger syndromeAmphetamine, past and present--a pharmacological and clinical perspectiveA review of anti-inflammatory agents for symptoms of schizophreniaLysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trialsIs it time to revisit the role of psychedelic drugs in enhancing human creativity?The adult psychiatrist's dilemma: psychostimulant use in attention deficit/hyperactivity disorderRefractory schizophrenia and atypical antipsychoticsReview: Benzodiazepines in generalized anxiety disorder: heterogeneity of outcomes based on a systematic review and meta-analysis of clinical trialsNicotinic receptor mechanisms and cognition in normal states and neuropsychiatric disorders.Differential contributions of serotonin receptors to the behavioral effects of indoleamine hallucinogens in miceHuman hallucinogen research: guidelines for safetyThe safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot studyMystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months laterDurability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study.Chronic inhibition of GABA synthesis in the bed nucleus of the stria terminalis elicits anxiety-like behaviorSchizophrenia: a multisystem disease?Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of opennessAntipsychotic-induced sensitization and tolerance: Behavioral characteristics, developmental impacts, and neurobiological mechanismsPropranolol for the treatment of anxiety disorders: Systematic review and meta-analysisNegative modulation of α₅ GABAA receptors in rats may partially prevent memory impairment induced by MK-801, but not amphetamine- or MK-801-elicited hyperlocomotionPharmacotherapy of adolescent attention deficit hyperactivity disorder: challenges, choices and caveatsReciprocal autoreceptor and heteroreceptor control of serotonergic, dopaminergic and noradrenergic transmission in the frontal cortex: relevance to the actions of antidepressant agentsAntidepressant-like activity of amisulpride in two animal models of depressionThe serotonin syndrome and its treatmentAmisulpride in medium-term treatment of dysthymia: a six-month, double-blind safety study versus amitriptyline. AMILONG investigatorsThe relationship between serotonergic function and the Psychopathy Checklist: Screening VersionTriazolam-amphetamine interaction: dissociation of effects on memory versus arousalMoclobemide discontinuation syndrome predominantly presenting with influenza-like symptomsmCPP: an undesired addition to the ecstasy marketAbuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuseDouble-blind, randomized sham controlled study of deep-TMS add-on treatment for negative symptoms and cognitive deficits in schizophreniaEffects of psilocybin on time perception and temporal control of behaviour in humansPhase I studies on the safety, tolerability, pharmacokinetics and pharmacodynamics of SB-649868, a novel dual orexin receptor antagonistOstracising caffeine from the pharmacological arsenal for attention-deficit hyperactivity disorder--was this a correct decision? A literature reviewThe neuronal noradrenaline transporter, anxiety and cardiovascular diseaseTrazodone and its active metabolite m-chlorophenylpiperazine as partial agonists at 5-HT1A receptors assessed by [35S]GTPgammaS bindingEfficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treatment of patients with major depressive disorder: two randomized, placebo- and active-controlled clinical trialsThe comparative psychopathology of affective disorders in animals and humansThe subjective experience of acute, experimentally-induced Salvia divinorum inebriation
P1433
Q22241794-290955BC-6814-481D-A0CF-39FB7B7FCE88Q22241824-EEFCA034-4D7C-43A5-B6A8-931E536B512EQ22241826-A7F6983A-74B4-409B-A85C-4518F1FBD7DFQ22241827-A2EC2AC5-B386-4235-899E-A26A8A81B350Q22241828-244A8680-12CC-4683-85FD-92CF4435EFBEQ22241829-76953085-DD1B-49F4-AA08-1621322FDCE7Q22241830-AFA0DDFE-1B9F-4EB3-94B2-98A21FE8269FQ22241831-E22F35D1-6580-4C6B-8819-F68A4075B6ABQ22306242-54819BAF-7165-49FB-9CA2-2F9454810902Q24532028-373A0AC3-A48A-495D-8C37-A2FBC41BDF55Q24594834-0059FE1E-F7BB-40B6-BEAF-9122C0B0389FQ24600704-2057F2DE-14AD-4B29-BB4A-DEEFD665C7A3Q24606265-D653D684-49BB-494B-9F34-91DCF9257CA2Q24606321-470CA10D-2ABE-4B40-A757-AF439D9FEE9CQ24620135-64720685-CE80-4D3C-BE5D-5E3016B7BEE7Q24631248-0D67AF4C-3E6E-4982-8750-03FAC2B7C620Q24633845-EB5E9A16-3F1E-4B9D-9968-5E6AF6068D42Q24634013-46367860-2C32-4298-A427-489167A61D2FQ26745506-3BAD96EF-F376-4867-BFD6-B74506714BB1Q26781133-3B51F066-B53B-4ACF-96E0-4BC99922E873Q27325106-69F5D269-30F7-4781-9306-366D97A5AACBQ28138163-113A8919-39E2-469D-AB69-AA2902948C56Q28140526-4AF0471C-AA01-4CBB-AAE5-21FD6F7A06FDQ28141401-0A9A95DF-4E27-4580-8B99-869613D9D326Q28142633-63909A8A-E4F7-45F0-B6C5-4DBEE2E0700BQ28145551-758ED2AD-D5F3-4019-A92B-EE8B05CA77DBQ28188088-76564B18-30B8-4A26-8018-62A638588134Q28189221-0F1DB16B-021E-47B8-A7ED-EB164DF58D39Q28202313-3AD0BE60-74E0-4EB6-9953-B6FB7E9414C0Q28238953-24C73A2E-166E-496F-8B16-9F234D15215CQ28239619-9306139D-873B-4722-9511-50196CC0C4C1Q28240086-DAC6549B-1FCE-4C49-86DA-763125510175Q28241533-0B20A9EF-5442-4D19-A007-D41C97A318F7Q28242421-B7709151-C2E9-458C-ABC9-E1A7C1C94606Q28243209-7BE6021F-3AC9-4106-B232-C070EEB45060Q28247061-380091D8-BE61-4908-AF18-7AE23EB8CDA8Q28250122-676F6E97-91B4-4EA8-B640-AE71C0E3B958Q28252146-B4B3DE10-440F-454C-B7CD-0A5AC941C571Q28255193-52F678B3-5CDC-45CC-B3B9-7FEB7327EBE6Q28257248-11A90163-FE0A-45F2-91A6-73071BF34B08
P1433
description
begutachtete wissenschaftliche Zeitschrift
@de
peer-reviewed scientific journal
@en
revista científica
@es
rivista scientifica
@it
vědecký časopis
@cs
wetenschappelijk tijdschrift van SAGE Publications
@nl
рецензований науковий журнал
@uk
वैज्ञानिक पत्रिका
@hi
name
Journal of Psychopharmacology
@ast
Journal of Psychopharmacology
@da
Journal of Psychopharmacology
@de
Journal of Psychopharmacology
@en
Journal of Psychopharmacology
@es
Journal of Psychopharmacology
@fi
Journal of Psychopharmacology
@fo
Journal of Psychopharmacology
@fr
Journal of Psychopharmacology
@is
Journal of Psychopharmacology
@it
type
label
Journal of Psychopharmacology
@ast
Journal of Psychopharmacology
@da
Journal of Psychopharmacology
@de
Journal of Psychopharmacology
@en
Journal of Psychopharmacology
@es
Journal of Psychopharmacology
@fi
Journal of Psychopharmacology
@fo
Journal of Psychopharmacology
@fr
Journal of Psychopharmacology
@is
Journal of Psychopharmacology
@it
prefLabel
Journal of Psychopharmacology
@ast
Journal of Psychopharmacology
@da
Journal of Psychopharmacology
@de
Journal of Psychopharmacology
@en
Journal of Psychopharmacology
@es
Journal of Psychopharmacology
@fi
Journal of Psychopharmacology
@fo
Journal of Psychopharmacology
@fr
Journal of Psychopharmacology
@is
Journal of Psychopharmacology
@it
P243
P3181
P1055
P1058
P1156
P1159
P1160
J. Psychopharmacol.
P123
P1277
P1476
Journal of Psychopharmacology
@en
P236
P243
P407
P571
1987-01-01T00:00:00Z